Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR) ovarian carcinoma (OVCA).

5580 Background: Based on clinical data and the partially non-cross-resistance of oxaliplatin with other platinum compounds, this phase II trial evaluated the safety and efficacy of a modified FOLFOX6 regimen in pts with PRR OVCA with a platinum-free interval of less than 6 months after any previous platinum-containing line of therapy. Methods: From 10/2008 till 08/2013, a total of 43 eligible pts with measurable (RECIST) and/or evaluable (CA125) disease were included in this study and received a median number of 8 courses (range: 1-14) of a modified FOLFOX6 regimen consisting in oxaliplatin 85 mg/m² d1, L-leucovorin 200 mg/m² d1 followed by a continuous iv infusion of 5-FU 2600 mg/m²/48hrs every 2 weeks until disease progression or unacceptable toxicity. Pt characteristics: median age 57 years (range: 37-81), median PS 1 (0-2), serous histological subtype 60%, median number of previous lines 3 (1-12), prior exposure to carboplatin 100%, paclitaxel 98%, pegylated liposomal doxorubicin 63%, gemcitabine 23%...